文献速递糖尿病

检查点抑制剂相关自身免疫性糖尿病(CIADM)的危险因素与特征:系统综述及与1型糖尿病的区分

Risk Factors and Characteristics of Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus (CIADM): A Systematic Review and Delineation From Type 1 Diabetes.
PubMed 文献 · Diabetes Care · 2023-01-01

该系统综述检索MEDLINE和PubMed数据库2014年至2022年4月的英文全文,最终纳入192例符合诊断标准的CIADM患者。患者平均年龄63.4±12.4岁,几乎所有患者(99.5%)有抗PD1或抗PD-L1治疗史,中位发病时间12周,69.7%发生DKA,40.4%T1D自身抗体阳性,且自身抗体阳性与DKA及更早发病显著相关。

要点

  • CIADM患者中69.7%以糖尿病酮症酸中毒(DKA)起病。
  • T1D自身抗体阳性率40.4%,与DKA(P=0.0009)和更早发病(P=0.02)相关。
  • 中位发病时间为12周(四分位距6-24周)。

核心结论

  • CIADM常以DKA起病,虽然T1D自身抗体仅40.4%阳性,但自身抗体与更早、更严重的临床表现相关。

研究设计与样本

  • 系统综述,检索MEDLINE和PubMed数据库2014年至2022年4月的英文全文,最终纳入192例符合诊断标准的CIADM患者进行分析。

主要发现

  • 患者平均年龄63.4±12.4岁,99.5%(除1例外)有抗PD1或抗PD-L1治疗史。
  • 91例接受检测的患者中59.3%具有T1D易感单倍型。
  • 中位发病时间12周(四分位距6-24周)。
  • DKA发生率为69.7%,初始C肽低者占91.6%。
  • T1D自身抗体阳性率为40.4%(73/179),与DKA显著相关(P=0.0009),与更早发病显著相关(P=0.02)。

关键数值与推荐

  • CIADM诊断标准:高血糖(血糖>11 mmol/L或HbA1c≥6.5%)且胰岛素缺乏(C肽<0.4 nmol/L和/或DKA)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 随访数据、脂肪酶和HLA单倍型检测的报告有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Checkpoint inhibitor-associated autoimmune diabetes mellitus (CIADM) is a distinct form of autoimmune diabetes that is a rare complication of immune checkpoint inhibitor therapy. Data regarding CIADM are limited. PURPOSE: To systematically review available evidence to identify presentation characteristics and risk factors for early or severe presentations of adult patients with CIADM. DATA SOURCES: MEDLINE and PubMed databases were reviewed. STUDY SELECTION: English full text articles from 2014 to April 2022 were identified with a predefined search strategy. Patients meeting diagnostic criteria for CIADM with evidence of hyperglycemia (blood glucose level >11 mmol/L or HbA1c ≥6.5%) and insulin deficiency (C-peptide <0.4 nmol/L and/or diabetic ketoacidosis [DKA]) were included for analysis. DATA EXTRACTION: With the search strategy we identified 1,206 articles. From 146 articles, 278 patients were labeled with "CIADM," with 192 patients meeting our diagnostic criteria and included in analysis. DATA SYNTHESIS: Mean ± SD age was 63.4 ± 12.4 years. All but one patient (99.5%) had prior exposure to either anti-PD1 or anti-PD-L1 therapy. Of the 91 patients tested (47.3%), 59.3% had susceptibility haplotypes for type 1 diabetes (T1D). Median time to CIADM onset was 12 weeks (interquartile range 6-24). DKA occurred in 69.7%, and initial C-peptide was low in 91.6%. T1D autoantibodies were present in 40.4% (73 of 179) and were significantly associated with DKA (P = 0.0009) and earlier time to CIADM onset (P = 0.02). LIMITATIONS: Reporting of follow-up data, lipase, and HLA haplotyping was limited. CONCLUSIONS: CIADM commonly presents in DKA. While T1D autoantibodies are only positive in 40.4%, they associate with earlier, more severe presentations.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Wu L, Tsang V, Menzies AM, et al. Risk Factors and Characteristics of Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus (CIADM): A Systematic Review and Delineation From Type 1 Diabetes. Diabetes Care. 2023. PMID: 37220262. doi:10.2337/dc22-2202

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。